Novo Nordisk fails to dismiss investor suit over CagriSema readout
The securities case over how Novo described its cagrilintide-semaglutide trial results now proceeds past the motion-to-dismiss stage.
DO
By Daniel Okafor · Regulatory Correspondent
Jul 29 03:00 ETSource: Fierce Biotech
The wire
- 01A court declined to throw out the investor lawsuit centered on Novo Nordisk's disclosures around the CagriSema obesity trial readout, Fierce Biotech reports.
- 02The amylin-plus-GLP-1 combination is Novo's lead answer to Eli Lilly in obesity, so litigation over how its data were framed keeps scrutiny on the program's messaging.
- 03Surviving dismissal is a procedural step, not a finding of liability; the case still has to go through discovery and any eventual ruling on the merits.
From the source
Read at fiercebiotech.comNovo Nordisk fails to dismiss lawsuit over CagriSema readout